Radiation Toxicity-Pipeline Review, H1 2017

Radiation Toxicity-Pipeline Review, H1 2017


  • Products Id :- GMDHC9220IDB
  • |
  • Pages: 202
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Radiation Toxicity-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity-Pipeline Review, H1 2017, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 5, 7, 46, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Radiation Toxicity (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Toxicology).

The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Radiation Toxicity (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Radiation Toxicity (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Toxicology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Overview 9

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 15

Products under Development by Companies 16

Products under Development by Universities/Institutes 20

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 24

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Companies Involved in Therapeutics Development 31

Aeolus Pharmaceuticals Inc 31

Angion Biomedica Corp 31

Atox Bio Ltd 32

BCN Biosciences LLC 32

Bolder Biotechnology Inc 33

Cellerant Therapeutics Inc 33

Cellphire Inc 34

Chrysalis BioTherapeutics Inc 34

Cleveland BioLabs Inc 35

Daiichi Sankyo Company Ltd 35

FirstString Research Inc 36

Foresee Pharmaceuticals LLC 36

Galera Therapeutics Inc 37

Genzyme Corp 37

GNI Group Ltd 38

Humanetics Corp 38

Insys Therapeutics Inc 39

Meabco A/S 39

Neumedicines Inc 40

Nohla Therapeutics Inc 40

Onconova Therapeutics Inc 41

Original BioMedicals Co Ltd 41

PharmaIN Corp 42

Pluristem Therapeutics Inc 42

RDD Pharma Ltd 43

Reata Pharmaceuticals Inc 43

RedHill Biopharma Ltd 44

RxBio Inc 44

Shuttle Pharmaceuticals LLC 45

SK Chemicals Co Ltd 45

Soligenix Inc 46

Synedgen Inc 46

Tonix Pharmaceuticals Holding Corp 47

TSRL Inc 47

viDA Therapeutics Inc 48

Windtree Therapeutics Inc 48

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Drug Profiles 49

(levocetirizine dihydrochloride + montelukast sodium)-Drug Profile 49

A-02-Drug Profile 50

AB-103-Drug Profile 51

ABC-294640-Drug Profile 54

AEOL-10171-Drug Profile 61

Aerosurf-Drug Profile 62

amifostine-Drug Profile 67

amifostine-Drug Profile 68

AVMOC-001-Drug Profile 69

BB-3-Drug Profile 70

BBT-007-Drug Profile 74

BBT-015-Drug Profile 75

BBT-018-Drug Profile 76

BBT-059-Drug Profile 77

BCN-057-Drug Profile 78

BIO-300-Drug Profile 79

BMX-001-Drug Profile 82

BPC-2-Drug Profile 84

C-2E2-Drug Profile 85

C-2E5-Drug Profile 86

Cell Therapy for Acute Radiation Syndrome-Drug Profile 87

cerium oxide-Drug Profile 88

CLT-009-Drug Profile 89

Des-Asp Angiotensin 1-Drug Profile 90

DG-3-Drug Profile 91

entolimod-Drug Profile 92

EWA-001-Drug Profile 99

Fibrinoplate-S-Drug Profile 100

FP-045-Drug Profile 101

Granexin-Drug Profile 102

HSJ-0017-Drug Profile 104

JP4-039-Drug Profile 105

LGM-2605-Drug Profile 107

m-2A2-Drug Profile 108

MDY-1001-Drug Profile 109

molgramostim-Drug Profile 110

NAS-911-Drug Profile 111

NMIL-121-Drug Profile 113

omaveloxolone-Drug Profile 117

ondansetron hydrochloride-Drug Profile 120

ondansetron hydrochloride CR-Drug Profile 121

Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis-Drug Profile 128

pirfenidone-Drug Profile 129

PLXR-18-Drug Profile 131

Preimplantation Factor-Drug Profile 138

QR-205-Drug Profile 139

RDD-2007-Drug Profile 140

recilisib sodium-Drug Profile 141

Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity-Drug Profile 143

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis-Drug Profile 144

Recombinant Protein to Activate FGF-4 for Radiation Injury-Drug Profile 145

Recombinant Protein to Activate FGF-7 for Radiation Injury-Drug Profile 146

RP-239X-Drug Profile 147

RS-9-Drug Profile 148

rusalatide acetate-Drug Profile 149

Rx-100-Drug Profile 153

sargramostim-Drug Profile 155

SGX-201-Drug Profile 158

SGX-202-Drug Profile 159

SKI-2162-Drug Profile 162

Small Molecule for Prostate Cancer, Asthma and Radiation Injury-Drug Profile 163

Small Molecule for Radiation Toxicity-Drug Profile 164

Small Molecule for Radiation Toxicity 1-Drug Profile 165

Small Molecule to Antagonize Adenosine A2A Receptor for Radiation Dermatitis-Drug Profile 166

Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology-Drug Profile 167

SP-3001-Drug Profile 168

ST-266-Drug Profile 169

ST-7-Drug Profile 172

SY-513-Drug Profile 173

SYGN-305-Drug Profile 174

SYGN-399-Drug Profile 175

Thrombosomes-Drug Profile 176

TNX-701-Drug Profile 177

TPO-7630-Drug Profile 178

TPO-7640-Drug Profile 180

VEDA-1209-Drug Profile 181

VTI-1000 Series-Drug Profile 182

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects 183

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Discontinued Products 186

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Product Development Milestones 187

Featured News & Press Releases 187

Appendix 196

Methodology 196

Coverage 196

Secondary Research 196

Primary Research 196

Expert Panel Validation 196

Contact Us 196

Disclaimer 197

List of Figures

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Aeolus Pharmaceuticals Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Angion Biomedica Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Atox Bio Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by BCN Biosciences LLC, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Bolder Biotechnology Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cellerant Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cellphire Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Chrysalis BioTherapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cleveland BioLabs Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by FirstString Research Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Galera Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Genzyme Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by GNI Group Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Humanetics Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Insys Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Meabco A/S, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Neumedicines Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Nohla Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Onconova Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Original BioMedicals Co Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by PharmaIN Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Pluristem Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by RDD Pharma Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Reata Pharmaceuticals Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by RedHill Biopharma Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by RxBio Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Shuttle Pharmaceuticals LLC, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by SK Chemicals Co Ltd, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Soligenix Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Synedgen Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by TSRL Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by viDA Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Windtree Therapeutics Inc, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects, H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects, H1 2017 (Contd..1), H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects, H1 2017 (Contd..2), H1 2017

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aeolus Pharmaceuticals Inc, Angion Biomedica Corp, Atox Bio Ltd, BCN Biosciences LLC, Bolder Biotechnology Inc, Cellerant Therapeutics Inc, Cellphire Inc, Chrysalis BioTherapeutics Inc, Cleveland BioLabs Inc, Daiichi Sankyo Company Ltd, FirstString Research Inc, Foresee Pharmaceuticals LLC, Galera Therapeutics Inc, Genzyme Corp, GNI Group Ltd, Humanetics Corp, Insys Therapeutics Inc, Meabco A/S, Neumedicines Inc, Nohla Therapeutics Inc, Onconova Therapeutics Inc, Original BioMedicals Co Ltd, PharmaIN Corp, Pluristem Therapeutics Inc, RDD Pharma Ltd, Reata Pharmaceuticals Inc, RedHill Biopharma Ltd, RxBio Inc, Shuttle Pharmaceuticals LLC, SK Chemicals Co Ltd, Soligenix Inc, Synedgen Inc, Tonix Pharmaceuticals Holding Corp, TSRL Inc, viDA Therapeutics Inc, Windtree Therapeutics Inc

select a license

Single User License
USD 2000 INR 129560
Site License
USD 4000 INR 259120
Corporate User License
USD 6000 INR 388680

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com